About Us



MABT was founded in 2011 with the mission of eradicating life-threatening infectious diseases using a transformative, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. This revolutionary type of immune system-based therapy is called “immunotherapy”.
 
Fundamentally, we are a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases (eg, Tamiflu alternative for influenza), emerging infectious diseases and biodefense. In addition, MABT is the first company to have received a valuable regulatory incentive called Orphan Drug Designation for late-stage rabies disease. Orphan Drug Designation offers a unique opportunity for ensuring a more rapid, efficient pathway to FDA approval and extended market exclusivity.

Home

Mid-Atlantic BioTherapeutics

Focus
Immunotherapy
Research

Antibiotic Resistance is Rapidly Growing

99
Anti-B Resistance
99
Cancer
99
Diabetes
99
Road Accidents

Our World is Changing

Antibiotic Resistance
Antibiotic Resistance
May 15, 2018
Outside the US, over 700,000 deaths are currently attributed to resistant bacteria. However, given recent trends in resistance, these numbers are expected to skyrocket to over 10,000,000 dea...
Fatality Rates
Fatality Rates
May 15, 2018
Rabies represents a unique unmet medical need, for which there is no effective therapy. Rabies is the most lethal organism known to the medical community, with a fatality rate of essentially...
Global Anti-Infectives Market
Global Anti-Infectives Market
May 15, 2018
Infectious diseases are one of the leading causes of morbidity and mortality throughout the world. The global market for all infectious diseases is expected to be ~$100 billion dollars by 20

We're ready to change the world.

Visit Us On Linkedin